How do anti-SARS-CoV-2 IgG and IgM predict the titre of virus-neutralizing antibodies in donors of convalescent plasma against COVID-19 disease?
Authors:
A. Entrová 1; K. Azeem 2; J. Vlčková 2; J. Smital 1; S. Zatloukalová 2; J. Ševčíková 2; H. Kollárová 2; D. Horáková 2
Authors‘ workplace:
Transfuzní oddělení, FN Olomouc
1; Ústav veřejného zdravotnictví, LF UP, Olomouc
2
Published in:
Transfuze Hematol. dnes,28, 2022, No. 4, p. 203-210.
Category:
Original Papers
doi:
https://doi.org/10.48095/cctahd2022203
Overview
Convalescent plasma was one of the treatment modalities in patients with severe or moderate course of the new acute respiratory disease COVID-19. The basic condition for its administration is a suffi cient virus neutralizing antibody titre ≥160. The aim of the present study is the analysis of the data of convalescent anti-covid plasma donors of the Transfusion Department of the Olomouc University Hospital, specifi cally to compare the correlation of serological tests of anti-SARS-CoV-2 antibodies with the virus neutralization test.
Keywords:
COVID-19 – convalescent plasma – anti-SARS-CoV-2 – VNT
Sources
1. Státní zdravotní ústav. Onemocnění novým koronavirem 2019-nCoV, nově pojmenovaným jako „COVID-19“ (coronavirus disease 2019). Praha: 2019. Dostupné z: http:/ / www. szu.cz/ uploads/ Epidemiologie/ Coronavirus/ Zakladni_ info/ 20200212_Onemocneni_novym_ koronavirem_2019.pdf.
2. Mezioborové stanovisko k podávání rekonvalescentní plazmy u pacientů s covid-19 (evidenční číslo ČSARIM: 18/ 2021).
3. European Commission Directorate-General For Health And Food Safety: An EU programme of COVID-19 convalescent plasma collection and transfusion: Guidance on collection, testing, processing, storage, distribution and monitored use. Brussels, 2021. Dostupné z: https:/ / ec. europa.eu/ health/ system/ files/ 2021-03/ guidance_ plasma_covid19_en_0.pdf.
4. Vyhláška č. 143/ 2008 Sb. Vyhláška o stanovení bližších požadavků pro zajištění jakosti a bezpečnosti lidské krve a jejích složek (vyhláška o lidské krvi)
5. Wendel S, Kutner JM, Machado R, et al. Screen ing for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. Transfusion. 2021;60(12):2938–2951.
6. Wendel S, Fontao-Wendel R, Fachini R, et al. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections. Transfusion. 2021;61(5):1447–1460.
7. Zelená H. Testování neutralizačních protilátek proti SARS-CoV-2. Ostrava: 2020. Dostupné z: https:/ / zuova.cz/ Home/ Clanek/ testovani-neutralizacnich- protilatek-proti-covid.
8. Bohoněk M. Výroba a použití rekonvalescentní plazmy pro léčbu onemocnění COVID-19 v ČR – stručná informace. Transfuze Hematol Dnes. 2021;27(2):189–190.
9. Carter JA, Freedenberg AT, Romeiser JL, et al. Impact of serological and PCR testing requirements on the selection of COVID- 19 convalescent plasma donors. Transfusion. 2021;61(5):1461–1470.
10. Klein S, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141–6150
11. Chvatal-Medina M, Mendez-Cortina Y, Patino PJ, Velilla PA, Rugeles MT. Antibody Responses in COVID-19: A Review. Front Immunol. 2021;12:633184.
12. Kallaste A, Kisand K, Aart A, Kisand K, Peterson P, Lember M. Antibody levels remain high to one-year‘s follow-up after moderate and severe COVID-19, but not after mild cases. Infect Dis (Lond). 2021;1–11.
13. Bläckberg A, Fernström N, Sarbrant E, Rasmussen M, Sunnerhagen T. Antibody kinetics and clinical course of COVID-19 a prospective observational study. PLoS One. 2021;16(3):e0248918.
14. Harvala H, Robb ML, Watkins N et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med. 2021;31(3):167–175.
15. Benner SE, Patel EU, Laeyendecker O et al. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. J Infect Dis. 2020;222(12): 1974–1984.
16. Tiwari AK, Negi G, Jaiswal RM et al. Correlation of sample-to-cut-off ratio of anti-SARS- -CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India. ISBT Sci Ser. 2021;16:269–275.
17. Mendrone-Junior A, Dinardo CL, Ferreira SC, et al. Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing. Transfusion. 2021;61(4):1181–1190.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2022 Issue 4
Most read in this issue
- Haemolytic disease of the foetus and new-born
- Beta-thalassemia minor and maior in pregnancy
- Current experience with ropeginterferon Alfa-2b in Ph negative myeloproliferative neoplasm at the Department of Internal Medicine – Haematology and Oncology in Brno
- How do anti-SARS-CoV-2 IgG and IgM predict the titre of virus-neutralizing antibodies in donors of convalescent plasma against COVID-19 disease?